title: Nongastrointestinal mucosa-associated lymphoid tissue (MALT) lymphomas: clinical and therapeutic features of 24 localized patients.
abstract: BACKGROUND
  Peripheral B-cell lymphoma of the marginal zone (MALT, low-grade), presenting as localized, extranodal disease, usually affects the elderly. The gastrointestinal tract is the most frequently involved extranodal location, representing 70% of all MALT lymphomas. Recently, numerous other extranodal sites involved by MALT lymphomas have also been described.
  
  
  METHODS
  From January 1990 to October 1995, 24 patients with untreated nongastrointestinal low-grade MALT lymphoma were submitted to treatments ranging from the local approach of radiotherapy and local alpha-interferon (alpha-IFN) administration to chemotherapy. The tumours were located in the lung (seven cases), conjunctiva (four cases), lachrymal gland and orbital soft tissue (four cases), salivary glands (three cases), skin (three cases), breast (two cases), and thyroid (one case). All patients had low-grade stage IE tumours.
  
  
  RESULTS
  Chemotherapy was administered in 11 patients (six with lung, three with salivary gland, one with breast, and one with thyroid locations); radiation therapy was employed in seven patients (three with lachrymal gland, three with skin, and one with breast locations); local alpha-IFN administration was administered in five patients (four with conjunctival, and one with lachrymal gland sites); and surgery was employed in one patient with a lung tumour. All patients achieved complete remissions; three local recurrences and two relapses in other sites were observed. The global five-year survival rate was 100% with a relapse-free survival rate of 79%.
  
  
  CONCLUSIONS
  These data confirm the significant efficacy of different therapeutic approaches to specific sites inbes obtaining a good remission rate for nongastrointestinal localized low-grade MALT lymphomas.
authors.affiliation: Institute of Hematology and Oncology Seràgnoli, Bologna, Italy.
authors.forename: P L
authors.initials: PL
authors.lastname: Zinzani
authors.forename: M
authors.initials: M
authors.lastname: Magagnoli
authors.forename: S
authors.initials: S
authors.lastname: Ascani
authors.forename: P
authors.initials: P
authors.lastname: Ricci
authors.forename: V
authors.initials: V
authors.lastname: Poletti
authors.forename: F
authors.initials: F
authors.lastname: Gherlinzoni
authors.forename: G
authors.initials: G
authors.lastname: Frezza
authors.forename: M
authors.initials: M
authors.lastname: Bendandi
authors.forename: C
authors.initials: C
authors.lastname: Stefanetti
authors.forename: E
authors.initials: E
authors.lastname: Merla
authors.forename: S
authors.initials: S
authors.lastname: Pileri
authors.forename: S
authors.initials: S
authors.lastname: Tura
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D018442:Lymphoma, B-Cell, Marginal Zone / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D016898:Interferon-alpha